Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Lines Up Launches As It Builds Out Biosimilars Business

Generics Sales Remain Flat In Q3, But Alymsys Bevacizumab Biosimilar Makes Solid Start

Executive Summary

Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.

You may also be interested in...



Amneal Makes It Three With Pegfilgrastim Approval

Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.

Amneal Sets $200m Sales Ambition For Biosimilar Trio

Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.

Amneal Delivers On Biosimilars Ambitions With Neupogen Rival

Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel